Table 1 Baseline characteristics
Variable | Total (N = 224) |
|---|---|
Age, years (mean ± SD) | 70.27 ± 8.85 |
PSA at diagnosis, ng/mL (mean ± SD) | 531.02 ± 1055.28 |
Biopsy Gleason score, n (%) | Â |
 6–7 | 26 (11.6) |
 8 | 56 (25.0) |
 9–10 | 142 (63.4) |
Imaging modality, n (%) | |
 CI | 101 (45.1) |
 18F-PSMA-1007 PET/CT | 24 (10.7) |
 Both CI and 18F-PSMA-1007 PET/CT | 99 (44.2) |
Primary treatment modality, n (%) | |
 ADT | 94 (41.9) |
 ADT + Docetaxel | 130 (58.1) |
Tumor volume, n (%) | |
 Low | 92 (41.1) |
 High | 132 (58.9) |
T stage, n (%) | |
 cT2 | 62 (27.7) |
 cT3 | 80 (35.7) |
 cT4 | 82 (36.6) |
N stage, n (%) | |
 N0 | 85 (37.9) |
 N1 | 139 (62.1) |
Metastasis site, n (%) | |
 NRLN | 55 (24.6) |
 Bone | 208 (92.9) |
 Visceral | 22 (9.8) |
Median PFS, months (mean ± SD) | 17.56 ± 8.32 |
Median follow-up, months (mean ± SD) | 27.38 ± 8.69 |